Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
179 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Allergic Rhinitis - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Allergic Rhinitis - Pipeline Review, H2 2016', provides an overview of the Allergic Rhinitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis - The report reviews pipeline therapeutics for Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Allergic Rhinitis therapeutics and enlists all their major and minor projects - The report assesses Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Allergic Rhinitis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Allergic Rhinitis Overview 9 Therapeutics Development 10 Pipeline Products for Allergic Rhinitis - Overview 10 Pipeline Products for Allergic Rhinitis - Comparative Analysis 11 Allergic Rhinitis - Therapeutics under Development by Companies 12 Allergic Rhinitis - Therapeutics under Investigation by Universities/Institutes 16 Allergic Rhinitis - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Allergic Rhinitis - Products under Development by Companies 20 Allergic Rhinitis - Products under Investigation by Universities/Institutes 25 Allergic Rhinitis - Companies Involved in Therapeutics Development 26 3M Drug Delivery Systems 26 Accolade Pharmaceuticals, LLC 27 AFFiRiS AG 28 ALK-Abello A/S 29 Allergy Therapeutics Plc 30 Ampio Pharmaceuticals, Inc. 31 Array BioPharma Inc. 32 ASIT biotech s.a. 33 Axikin Pharmaceuticals, Inc. 34 Chong Kun Dang Pharmaceutical Corp. 35 Chrysalis BioTherapeutics, Inc. 36 ELORAC, Inc. 37 Faes Farma, S.A. 38 Fountain Biopharma Inc. 39 GlaxoSmithKline Plc 40 Glenmark Pharmaceuticals Ltd. 41 HAL Allergy BV 42 Hisamitsu Pharmaceutical Co., Inc. 43 Johnson & Johnson 44 Laboratorios LETI S.L. 45 Ligand Pharmaceuticals, Inc. 46 Marinomed Biotechnologie GmbH 47 Merck & Co., Inc. 48 Panmira Pharmaceuticals, LLC. 49 Paradigm Biopharmaceuticals Limited 50 Pfizer Inc. 51 Protectimmun GmbH 52 Roxall Medizin GmbH 53 Sanofi 54 Shionogi & Co., Ltd. 55 Stallergenes Greer plc 56 Sun Pharma Advanced Research Company Ltd. 57 Taiho Pharmaceutical Co., Ltd. 58 VentiRx Pharmaceuticals, Inc. 59 Xencor, Inc. 60 Allergic Rhinitis - Therapeutics Assessment 61 Assessment by Monotherapy Products 61 Assessment by Combination Products 62 Assessment by Target 63 Assessment by Mechanism of Action 65 Assessment by Route of Administration 67 Assessment by Molecule Type 69 Drug Profiles 71 (azelastine hydrochloride + budesonide) - Drug Profile 71 (fexofenadine hydrochloride + phenylephrine hydrochloride) - Drug Profile 72 (levocabastine hydrochloride + mometasone furoate) - Drug Profile 73 854-A - Drug Profile 74 Allergen for Allergic Asthma and Allergic Rhinitis - Drug Profile 75 Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile 76 Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 77 Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile 78 Allergen for Asthma and Perennial Allergic Rhinitis - Drug Profile 79 Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 80 Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 81 Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 82 Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 83 Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile 84 AM-211 - Drug Profile 85 AM-461 - Drug Profile 86 Ampion - Drug Profile 87 AR-460770 - Drug Profile 95 Arabinogalactan - Drug Profile 96 asapiprant - Drug Profile 97 B-244 - Drug Profile 98 beta-escin - Drug Profile 99 bilastine - Drug Profile 100 budesonide - Drug Profile 102 CBP-174 - Drug Profile 103 cidoxepin hydrochloride - Drug Profile 104 clustoid wiesenlieschgras - Drug Profile 105 desloratadine - Drug Profile 106 emedastine difumarate - Drug Profile 108 esketamine hydrochloride - Drug Profile 109 FB-825 - Drug Profile 112 gp-ASIT - Drug Profile 113 GSK-2245035 - Drug Profile 115 GSP-301 - Drug Profile 117 Lactococcus lactis G121 - Drug Profile 118 motolimod - Drug Profile 119 nasapaque - Drug Profile 122 pentosan polysulfate sodium - Drug Profile 123 PF-06444752 - Drug Profile 125 PF-06444753 - Drug Profile 127 Pollinex Quattro Tree - Drug Profile 129 rE58 - Drug Profile 131 Small Molecule for Allergic Rhinitis - Drug Profile 132 Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile 133 Small Molecule to Antagonize G Protein Coupled Receptors for Respiratory Disorders - Drug Profile 134 Small Molecule to Inhibit Soluble Epoxide Hydrolase for Sinusitis and Allergic Rhinitis - Drug Profile 135 Small Molecules to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis - Drug Profile 136 STAGR-120 - Drug Profile 137 standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile 138 standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile 140 SUN-0597 - Drug Profile 145 TAS-205 - Drug Profile 147 Vaccine to Target IgE for Allergic Rhinitis and Asthma - Drug Profile 148 VTX-1463 - Drug Profile 149 XmAb-7195 - Drug Profile 150 Zafi-3 - Drug Profile 151 Allergic Rhinitis - Dormant Projects 152 Allergic Rhinitis - Discontinued Products 162 Allergic Rhinitis - Product Development Milestones 165 Featured News & Press Releases 165 Appendix 174 Methodology 174 Coverage 174 Secondary Research 174 Primary Research 174 Expert Panel Validation 174 Contact Us 174 Disclaimer 175
List of Tables
Number of Products under Development for Allergic Rhinitis, H2 2016 15 Number of Products under Development for Allergic Rhinitis - Comparative Analysis, H2 2016 16 Number of Products under Development by Companies, H2 2016 17 Number of Products under Development by Companies, H2 2016 (Contd..1) 18 Number of Products under Development by Companies, H2 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2016 20 Comparative Analysis by Late Stage Development, H2 2016 21 Comparative Analysis by Clinical Stage Development, H2 2016 22 Comparative Analysis by Early Stage Development, H2 2016 23 Products under Development by Companies, H2 2016 24 Products under Development by Companies, H2 2016 (Contd..1) 25 Products under Development by Companies, H2 2016 (Contd..2) 26 Products under Development by Companies, H2 2016 (Contd..3) 27 Products under Development by Companies, H2 2016 (Contd..4) 28 Products under Investigation by Universities/Institutes, H2 2016 29 Allergic Rhinitis - Pipeline by 3M Drug Delivery Systems, H2 2016 30 Allergic Rhinitis - Pipeline by Accolade Pharmaceuticals, LLC, H2 2016 31 Allergic Rhinitis - Pipeline by AFFiRiS AG, H2 2016 32 Allergic Rhinitis - Pipeline by ALK-Abello A/S, H2 2016 33 Allergic Rhinitis - Pipeline by Allergy Therapeutics Plc, H2 2016 34 Allergic Rhinitis - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 35 Allergic Rhinitis - Pipeline by Array BioPharma Inc., H2 2016 36 Allergic Rhinitis - Pipeline by ASIT biotech s.a., H2 2016 37 Allergic Rhinitis - Pipeline by Axikin Pharmaceuticals, Inc., H2 2016 38 Allergic Rhinitis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 39 Allergic Rhinitis - Pipeline by Chrysalis BioTherapeutics, Inc., H2 2016 40 Allergic Rhinitis - Pipeline by ELORAC, Inc., H2 2016 41 Allergic Rhinitis - Pipeline by Faes Farma, S.A., H2 2016 42 Allergic Rhinitis - Pipeline by Fountain Biopharma Inc., H2 2016 43 Allergic Rhinitis - Pipeline by GlaxoSmithKline Plc, H2 2016 44 Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 45 Allergic Rhinitis - Pipeline by HAL Allergy BV, H2 2016 46 Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016 47 Allergic Rhinitis - Pipeline by Johnson & Johnson, H2 2016 48 Allergic Rhinitis - Pipeline by Laboratorios LETI S.L., H2 2016 49 Allergic Rhinitis - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 50 Allergic Rhinitis - Pipeline by Marinomed Biotechnologie GmbH, H2 2016 51 Allergic Rhinitis - Pipeline by Merck & Co., Inc., H2 2016 52 Allergic Rhinitis - Pipeline by Panmira Pharmaceuticals, LLC., H2 2016 53 Allergic Rhinitis - Pipeline by Paradigm Biopharmaceuticals Limited, H2 2016 54 Allergic Rhinitis - Pipeline by Pfizer Inc., H2 2016 55 Allergic Rhinitis - Pipeline by Protectimmun GmbH, H2 2016 56 Allergic Rhinitis - Pipeline by Roxall Medizin GmbH, H2 2016 57 Allergic Rhinitis - Pipeline by Sanofi, H2 2016 58 Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H2 2016 59 Allergic Rhinitis - Pipeline by Stallergenes Greer plc, H2 2016 60 Allergic Rhinitis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 61 Allergic Rhinitis - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 62 Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016 63 Allergic Rhinitis - Pipeline by Xencor, Inc., H2 2016 64 Assessment by Monotherapy Products, H2 2016 65 Assessment by Combination Products, H2 2016 66 Number of Products by Stage and Target, H2 2016 68 Number of Products by Stage and Mechanism of Action, H2 2016 70 Number of Products by Stage and Route of Administration, H2 2016 72 Number of Products by Stage and Molecule Type, H2 2016 74 Allergic Rhinitis - Dormant Projects, H2 2016 156 Allergic Rhinitis - Dormant Projects (Contd..1), H2 2016 157 Allergic Rhinitis - Dormant Projects (Contd..2), H2 2016 158 Allergic Rhinitis - Dormant Projects (Contd..3), H2 2016 159 Allergic Rhinitis - Dormant Projects (Contd..4), H2 2016 160 Allergic Rhinitis - Dormant Projects (Contd..5), H2 2016 161 Allergic Rhinitis - Dormant Projects (Contd..6), H2 2016 162 Allergic Rhinitis - Dormant Projects (Contd..7), H2 2016 163 Allergic Rhinitis - Dormant Projects (Contd..8), H2 2016 164 Allergic Rhinitis - Dormant Projects (Contd..9), H2 2016 165 Allergic Rhinitis - Discontinued Products, H2 2016 166 Allergic Rhinitis - Discontinued Products (Contd..1), H2 2016 167 Allergic Rhinitis - Discontinued Products (Contd..2), H2 2016 168
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
